DVT vs superficial thrombophlebitis
Formal Definition
Differentiation between two distinct venous thrombotic conditions: deep vein thrombosis (DVT) — a pathologic thrombus formation in a deep vein (typically lower extremity — femoral, popliteal, iliac, calf deep veins), with risk of embolization to the pulmonary vasculature (PE), requiring anticoagulation and carrying significant morbidity and mortality; versus superficial thrombophlebitis (also called superficial vein thrombosis or SVT) — inflammation and thrombosis in a superficial vein (great saphenous, small saphenous, accessory saphenous, cephalic, basilic) commonly occurring in varicose veins, post-IV cannulation, or trauma, typically self-limited with conservative management (warm compresses, NSAIDs, ambulation, leg elevation); differentiated clinically and confirmed with duplex ultrasonography (compression ultrasound).
How It's Used on the Ward
"DVT vs superficial thrombophlebitis" — the patient has a red, painful, tender cord-like area on their leg; DVT is the deep, dangerous one requiring anticoagulation; superficial thrombophlebitis is the superficial, usually benign one treated with NSAIDs and heat; both are forms of venous inflammation but the location and implications differ dramatically.
Example
""58-year-old with varicose veins presents with a tender, palpable, red cord along the medial calf extending from ankle to mid-calf. Warm to touch, mildly tender on palpation. Homan's sign negative. Duplex ultrasound: no deep vein thrombus; thrombosis confined to the great saphenous vein. Diagnosis: superficial thrombophlebitis (SVT). Treatment: NSAIDs (ibuprofen 600mg TID), warm compresses, ambulation, leg elevation. Symptoms resolve over 7-10 days. Contrast: 62-year-old post-op day 5 from hip surgery with calf swelling, tenderness to deep palpation, warmth, mild erythema. Duplex ultrasound: non-compressible popliteal vein with echogenic thrombus. Diagnosis: DVT. Started anticoagulation (rivaroxaban or enoxaparin bridge to warfarin).""
Clinical Context
Superficial thrombophlebitis: typically self-limited. Risk factors: varicose veins, IV cannulation, minor trauma, hypercoagulable states, pregnancy, oral contraceptives. Treatment: NSAIDs, warm compresses, ambulation; anticoagulation if thrombus is extensive (>5cm), located near the saphenofemoral junction (risk of progression to DVT), or in high-risk patient (active cancer, recent major surgery, thrombophilia) — SURPRISE trial showed rivaroxaban 10mg daily for 45 days reduced progression to DVT/PE. DVT diagnosis: Wells score (clinical probability assessment), D-dimer for low-probability exclusion, ultrasound (compression duplex) for confirmation. DVT treatment: anticoagulation duration depends on context — provoked (surgery, trauma, immobility, OCP) typically 3 months; unprovoked typically 3-6 months minimum with risk-benefit reassessment; recurrent or high-risk (active cancer) often 3-12 months or indefinite; distal (calf-only) DVT management is more nuanced. Red flags for superficial thrombophlebitis: ascending toward deep venous system (saphenofemoral junction), bilateral, recurrent, or in patients with active cancer — these warrant imaging and possible anticoagulation.